Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly

J Clin Endocrinol Metab. 2023 Apr 13;108(5):e193-e194. doi: 10.1210/clinem/dgac762.

Authors

David S McLaren^{1

2}, Robert D Murray^{1

2}

Affiliations

¹ Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds LS9 7TF, UK.
² Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds LS2 9JT, UK.

PMID: 36582134
DOI: 10.1210/clinem/dgac762

No abstract available

Keywords: acromegaly; lanreotide; octreotide; paltusotine; somatostatin.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Acromegaly* / drug therapy
Humans
Ligands
Octreotide
Receptors, Somatostatin
Somatostatin / therapeutic use

Substances

Receptors, Somatostatin
Ligands
Octreotide
Somatostatin